NASDAQ · BDTX
Black Diamond Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BDTX: Nov 5, 2026
Black Diamond Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.03. The reported EPS for the same quarter last year was $-0.15.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.03 | $0.62 | $-0.20 | 5 |
| Dec 2026 | $-0.22 | $-0.19 | $-0.30 | 5 |
| Mar 2027 | $-0.23 | $-0.15 | $-0.36 | 5 |
| Jun 2027 | $-0.25 | $-0.15 | $-0.41 | 5 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat · RTTNews- Zacks · Sep 4, 11:30 AM EDTBlack Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- MarketBeat · Jun 6, 5:04 AM EDTBlack Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA PathBlack Diamond Therapeutics (NASDAQ:BDTX) is positioning its lead oncology drug candidate, silevertinib, as a potential treatment for non-small cell lung cancer patients with non-classical EGFR mutations, Chief Executive Officer Mark Velleca said during a Jefferies fireside chat f
- Zacks · May 27, 11:16 AM EDTBDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh CatalystBlack Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
- Zacks · May 27, 11:13 AM EDTBlack Diamond Stock Outlook After Q1 Beat and Cash RunwayBDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
- Zacks · May 27, 11:10 AM EDTBDTX Silevertinib Data in EGFR NSCLC: What Investors Need to KnowBlack Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
- Zacks · May 25, 10:53 AM EDTBDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study DataBlack Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.
- RTTNews · May 22, 4:10 AM EDTBlack Diamond Plunges Despite Positive Phase 2 Results For Silevertinib In 1L NSCLC(RTTNews) – Black Diamond Therapeutics, Inc. (BDTX), a clinical-stage oncology company, announced positive results with 15.2 months of median Progression-free Survival from its Phase 2 trial of Silevertinib in frontline or 1L non-small cell lung cancer (NSCLC) patients with epide
- MarketBeat · May 21, 7:09 PM EDTBlack Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 StudyBlack Diamond Therapeutics (NASDAQ:BDTX) reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigational therapy produced a preliminary median progression-free survival of 15.2 mon
- RTTNews · May 20, 10:19 PM EDTSLXN On Track, IMVT Hits New High, CTEV Eyes Blockbuster Revenue, Big Day Ahead For BDTX(RTTNews) – In today's gainers' list, we cover HCW Biologics, its upcoming catalysts and going concern risks; Silexion's development progress of its lead drug candidate SIL204; Immunovant's encouraging rheumatoid arthritis data; why investors will be closely watching Black Diamon
- RTTNews · May 20, 5:01 AM EDTMTVA Gains Weight, CODX Takes A Shot At Ebola, EDSA To Reveal New Data, BDTX On Watch(RTTNews) – As hedge fund tycoon George Soros once said, "It's not whether you're right or wrong that's important, but how much money you make when you're right and how much you lose when you're wrong." The following biotech stocks were among the top gainers in Tuesday's trading
- Zacks · May 11, 11:48 AM EDTBDTX Shares Gain 11% in a Week: Here's What You Should KnowBlack Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and continued progress for lead candidate silevertinib.
- RTTNews · May 7, 11:43 AM EDTBlack Diamond Therapeutics Posts Q1 Loss, Highlights Progress On Silevertinib Programs; Stock Down(RTTNews) – Black Diamond Therapeutics, Inc. (BDTX), reported first-quarter 2026 financial results and provided a corporate update, underscoring continued progress across its MasterKey oncology pipeline, led by its fourth-generation EGFR inhibitor Silevertinib.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Black Diamond Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.